ArticleFrontiers in oncology2026
Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ALK-positive of anaplastic lymphoma kinase (ALK) is rare in lung squamous cell carcinoma (LSCC), with an incidence of less than 1%. The role of neoadjuvant treatment with ALK inhibitors remains understudied. Here, we report the first case of stage IIIB, ALK-positive LSCC that achieved complete pathologic responses (pCR) to neoadjuvant ensartinib. In the current study, EML4-ALK positivity was identified by next-generation sequencing in a case with locally SCC. Rapid partial response was observed after four weeks of ensartinib. The patient continued to receive 6 weeks of ensartinib followed by right upper lobectomy with complete pathological response. To the best of our knowledge, limited data are available regarding the role of ensartinib as a neoadjuvant therapy for ALK-positive, non-small cell lung cancer (NSCLC) patients. Our case provided evidence that locally advanced, ALK-positive LSCC could benefit from neoadjuvant ensartinib, with an impressive response and favorable safety. Our findings may also extend the indications for targeted therapy to the neoadjuvant setting in locally advanced, ALK-positive, resectable LSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.